Date: 2012-09-18
Type of information: Fundraising
Company: CureVac (Germany)
Investors: dievini Hopp BioTech (Germany)
Amount: €80 million
Funding type: series D financing round
Planned used: CureVac will use the proceeds mainly to advance the development of its two lead RNActive® cancer vaccines against prostate cancer and non-small cell lung cancer (NSCLC), respectively. Additionally, CureVac will intensify the development of its prophylactic vaccines and adjuvants for infectious diseases.
Others: CureVac, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, has announced the completion of an €80 million financing round with its main investor, dievini Hopp BioTech Holding. This financing round is one of the largest for a private European biotech company. To date, the company has raised approximately €145 million in equity financing.
CureVac previously announced its collaboration with DARPA, Sanofi Pasteur and In-Cell-Art to develop prophylactic and therapeutic vaccines for infectious diseases. The company has successfully completed Phase 1/2a studies with its RNActive cancer vaccines in prostate cancer and non small cell lung cancer.
Therapeutic area: Cancer - Oncology - Infectious diseases
